Applications of N-Boc-N'-Tosyl-D-Histidine in Industrial Manufacturing

Our production of N-Boc-N'-Tosyl-D-Histidine directly supports advanced synthesis in the pharmaceutical, peptide, and research chemical sectors. Below, we detail real-world industrial applications and specific integration details across major downstream segments.

1. Chiral Building Block for Peptide API Manufacturing

Pharmaceutical API manufacturers leverage N-Boc-N'-Tosyl-D-Histidine as an essential chiral protected amino acid during solid-phase peptide synthesis (SPPS). Its stable protecting groups stabilize the imidazole and amine during sequential coupling, minimizing racemization and improving overall peptide purity. Used primarily for the synthesis of D-histidine-containing APIs, including peptide hormone analogs and enzyme inhibitors, this raw material enters the process at the protected amino acid coupling stage, directly influencing the stereochemical fidelity and yield of final pharmaceutical peptides.

Industry compliance standards

• ICH Q7 (Good Manufacturing Practice for Active Pharmaceutical Ingredients)
• USP-NF (United States Pharmacopeia–National Formulary) for peptide APIs
• European Pharmacopoeia (Ph. Eur.) Peptide Monographs
• FDA 21 CFR Part 211 (cGMP for Finished Pharmaceuticals)

Typical usage ratio

• 1.0 equivalent relative to the target amine in peptide elongation; actual usage adjusted for coupling efficiency, with possible excess of 1.05–1.2 equivalents to account for process yield variance

Downstream process integration

• Introduced during protected amino acid loading or SPPS cycle; coupled via carbodiimide or uronium activation with in-line deprotection after sequence assembly

Final product types

• Pharmaceutical peptide APIs (e.g., D-histidine analogs, insulin derivatives, diagnostic peptides)
• Clinical-grade oligopeptides
• Customized D-amino acid-based research peptides

2. Intermediate for Chiral Ligand Synthesis in Homogeneous Catalysis

Catalyst development labs and fine chemical firms utilize this compound to prepare enantiopure ligands that rely on the D-histidine scaffold. The N-Boc and N'-Tosyl protections allow for multi-step transformations—including selective deprotection, metalation, and further functionalization—for the creation of novel chiral auxiliaries and organometallic complexes. Pure batch quality and controlled derivatization are critical at this stage to avoid downstream catalyst contamination in pharmaceutical or specialty operations.

Industry compliance standards

• ISO 9001:2015 (Quality Management Systems for Fine Chemicals)
• REACH Regulation (EC 1907/2006) for chemical intermediates
• OECD GLP (Good Laboratory Practice) for analytical support

Typical usage ratio

• 1.0–2.0 equivalents per ligand molecule backbone, adjusted for desired ligand configuration and stepwise derivatization strategy

Downstream process integration

• Added to reaction sequence for ligand core assembly, typically following activation of the imidazole or selective deprotection for site-specific metal coordination

Final product types

• Chiral ligands for asymmetric hydrogenation
• Transition metal ligand complexes for fine chemical synthesis
• Advanced intermediates for high-enantioselectivity catalysts

3. Protected Amino Acid Source for Custom Peptide Synthesis Services

Commercial peptide synthesis providers prioritize the use of this protected D-histidine derivative in the assembly of specialized peptides for academic, diagnostic, and industrial R&D. The product’s consistent purity supports batch-to-batch reproducibility, and its orthogonal protection allows tailored deprotection schedules for custom sequence designs, including difficult-to-synthesize D-histidine motifs required by research institutes and biotech firms.

Industry compliance standards

• ISO 13485 (Quality Management for Medical Devices—applicable to in vitro diagnostic peptides)
• USP General Chapter <1046> for Peptide Synthesis
• FDA QSR (Quality System Regulation) when producing components for regulated devices

Typical usage ratio

• 1.0 equivalent per D-histidine position in peptide chain, with increments of up to 1.15 equivalents in long or sterically hindered sequences

Downstream process integration

• Used in Fmoc/t-Boc SPPS platforms; introduced at the programmed histidine insertion step with selective deprotection for side chain or backbone modifications

Final product types

• Custom research peptides containing D-histidine
• Peptide calibrators and standards for mass spectrometry analysis
• In vitro diagnostic peptides and bioanalytical reagents

4. Raw Material for Peptidomimetic Drug Discovery Compounds

Drug discovery teams in biotech development employ this selectively protected D-histidine derivative to synthesize non-natural peptidomimetics, investigating improved stability or receptor selectivity in lead compound libraries. The raw material’s integrity under reaction conditions and compatibility with various synthetic protocols make it an enabling intermediate for SAR (structure-activity relationship) studies, with precise addition critical to iterative synthesis cycles and automated library generation platforms.

Industry compliance standards

• ISO 9001 (Quality requirements for research materials)
• IUPAC Nomenclature and Purity Guidelines for screening compounds
• Internal R&D cGMP for early-stage investigational compound synthesis

Typical usage ratio

• 0.9–1.2 equivalents per sequence, dependent on the complexity of the scaffold and required coupling efficiency for diversity generation

Downstream process integration

• Introduced in multi-step solution-phase synthesis routes; protected forms enable orthogonal deprotections and site-selective modification within automated synthesizer workflows

Final product types

• Sar library compounds for early drug screening
• Peptidomimetic scaffolds for hit-to-lead optimization
• Non-natural amino acid drug candidates